Clinical Trials

NCT06854159 | RECRUITING | PHASE2
34 participants

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-08
Start Date:
2025-08-07
Completion:
2028-10-31
Conditions
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
  • BIOLOGICAL
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page